We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Panel of Oligonucleotide Probes and Primers Ready for Influenza Researchers

By LabMedica International staff writers
Posted on 21 Apr 2010
Molecular biologists and virologists working on the influenza virus will welcome the introduction of a new panel of oligonucleotide probes and primers that may be used to resolve the genetic signatures of a variety of influenza strains.

The panel is being marketed by Biosearch Technologies (Novato, CA, USA) and is produced under license from the developer, the Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) and from F. More...
Hoffmann-La Roche (Basel, Switzerland).

The reagents – probes and primers – are intended for use in qPCR (quantitative real time polymerase chain reaction) protocols. The procedure for qPCR follows the general principle of polymerase chain reaction; its key feature is that the amplified DNA is detected as the reaction progresses in real time, compared to standard PCR, where the product of the reaction is detected at its end. Two common methods for detection of products in real-time PCR are (1) nonspecific fluorescent dyes that intercalate with any double-stranded DNA, and (2) sequence-specific DNA probes consisting of oligonucleotides that are labeled with a fluorescent reporter, which permits detection only after hybridization of the probe with its complementary DNA target.

The Biosearch Influenza A Subtyping ValuPanel Reagents comprise oligonucleotides based on the following seven signature sequences: universal strain of influenza A; influenza A H1 subtype; influenza A H3 subtype; influenza A H5a subtype; influenza A H5b subtype; universal strain of influenza B, and RNase P as a positive control.

"Over the past few years, Biosearch has developed advanced manufacturing capability and quality system management, which set us apart from traditional oligonucleotide suppliers,” said Dr. Ron Cook, president and CEO of Biosearch Technologies. "We are pleased to apply our expertise to provide these important new reagents for the detection of all major strains of influenza. We expect to augment this listing as new assays become available.”

Related Links:
Biosearch Technologies
Centers for Disease Control and Prevention
F. Hoffmann-La Roche



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.